Umicore is supporting pediatric oncology research with a donation of 5,000 euros

For the fourth consecutive year, the Precious Metals Chemistry division of the materials technology and recycling group Umicore is supporting the Parents’ Initiative for Children with Leukemia and Cancer at the University Hospital of Würzburg. “We are very pleased to once again present the association with a donation of 5,000 euros this year. “The experiences of recent years have shown how important it is to support those affected and that our donations have made a significant difference,” said Michael Schwarz, Director of Global API Business, at the donation ceremony.

Each year, the University Children’s Hospital treats approximately 90 to 100 children and adolescents who are receiving inpatient or outpatient care for a newly diagnosed malignant disease. With this donation, Umicore is supporting important research projects, including the development of novel therapeutic approaches, such as a tumor vaccine or the production of tumor-specific immune cells. The goal of the Würzburg researchers is to provide children and adolescents who cannot yet be permanently cured with a chance at long-term remission in the coming years.

“I am very grateful for the tremendous support from Umicore, which will help us develop new, cutting-edge therapies for our children with cancer,” explains Professor Dr. Paul Schlegel, Head of the Division of Pediatric Hematology, Oncology, and Stem Cell Transplantation at the University Hospital of Würzburg.

Umicore produces active pharmaceutical ingredients (APIs), which are essential for cancer treatment. At its Hanau site, the company conducts research on these substances and contributes to global cancer treatment in the field of highly active APIs.

Caption:

Michael Schwarz (right), Umicore, presents a donation check for 5,000 euros to the Department of Pediatric Oncology at the University Hospital of Würzburg.